Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| ABBV | AbbVie, Inc. | -1.53% | 89.33 | 1.9% | $1150.39m | |
| JNJ | Johnson & Johnson | -0.49% | 143.85 | 0.7% | $1050.38m | |
| BMY | Bristol-Myers Squibb Co. | -0.49% | 60.03 | 1.0% | $962.49m | |
| MRK | Merck & Co., Inc. | -0.03% | 77.24 | 0.7% | $834.15m | |
| PFE | Pfizer Inc. | -0.44% | 37.33 | 0.9% | $827.89m | |
| LLY | Eli Lilly & Co. | -2.27% | 144.60 | 1.1% | $414.21m | |
| AZN | AstraZeneca Plc | -2.11% | 51.99 | 1.2% | $248.80m | |
| NVS | Novartis AG | -1.00% | 84.20 | 0.2% | $155.21m | |
| GSK | GlaxoSmithKline Plc | 0.10% | 40.79 | 0.2% | $137.47m | |
| NVO | Novo Nordisk A/S | -1.45% | 62.48 | 0.1% | $84.39m | |
| SNY | Sanofi | 0.06% | 47.30 | 0.2% | $79.60m | |
| RGEN | Repligen Corp. | -5.41% | 126.14 | 7.1% | $66.10m | |
| BHVN | Biohaven Pharmaceutical Holding Co. Ltd. | -2.15% | 58.72 | 0.0% | $44.79m | |
| ARCT | Arcturus Therapeutics Holdings, Inc. | -29.67% | 38.19 | 0.0% | $38.70m | |
| RETA | Reata Pharmaceuticals, Inc. | -3.37% | 152.45 | 3.4% | $36.51m |
Company Profile
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.